Key finding — Psilocybin-assisted therapy significantly reduced heavy drinking days compared with active placebo over 32 weeks, suggesting potential for treating alcohol use disorder.
Study at a glance
| Field | Detail |
|---|---|
| Institution | NYU Langone |
| Design | Randomized, double-blind, placebo-controlled trial |
| Sample size | 95 participants |
| Intervention | Two psilocybin doses with psychotherapy vs. antihistamine active placebo |
| Year | 2022 |
| Condition | Alcohol use disorder |
| Journal | JAMA Psychiatry |
| Evidence | emerging |
Limitations
Functional unblinding likely; the psychotherapy component makes it hard to isolate the drug effect; needs replication in larger trials.
Editorial note
One of the strongest controlled signals for psilocybin beyond mood disorders, extending the evidence into addiction treatment with a relatively large, placebo-controlled design.
Summary written by MMI Editorial for clarity. Always consult the primary source for full methodology and results. The confidence rating reflects our assessment of evidence strength.